Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination.

Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, Overman RG, Ochsenbauer C, Edmonds TG, Kappes JC, Cunningham CK, Denny TN, Weinhold KJ, Ferrari G, Haynes BF, Koup RA, Graham BS, Roederer M, Tomaras GD.

J Virol. 2010 May;84(10):4998-5006. doi: 10.1128/JVI.00138-10. Epub 2010 Mar 3.

2.

Development of a DNA-MVA/HIVA vaccine for Kenya.

Hanke T, McMichael AJ, Mwau M, Wee EG, Ceberej I, Patel S, Sutton J, Tomlinson M, Samuel RV.

Vaccine. 2002 May 6;20(15):1995-8. Review.

PMID:
11983261
3.

Peptide-MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development.

Reguzova AY, Karpenko LI, Mechetina LV, Belyakov IM.

Expert Rev Vaccines. 2015 Jan;14(1):69-84. doi: 10.1586/14760584.2015.962520. Epub 2014 Nov 5. Review.

PMID:
25373312
4.

Vaccine design for CD8 T lymphocyte responses.

Koup RA, Douek DC.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007252. doi: 10.1101/cshperspect.a007252. Review.

5.

Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV.

Makedonas G, Betts MR.

Immunol Rev. 2011 Jan;239(1):109-24. doi: 10.1111/j.1600-065X.2010.00968.x. Review.

6.

Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease.

Chattopadhyay PK, Roederer M.

Cytometry A. 2010 Jul;77(7):614-22. doi: 10.1002/cyto.a.20905. Review.

Items per page

Supplemental Content

Write to the Help Desk